Xsolla Acquires Ludo to Advance Player Engagement and Monetization
8.5.2025 10:00:00 CEST | Business Wire | Press Release
Xsolla, a global leader in video game commerce, is pleased to announce the acquisition of Ludo, a platform designed to drive community engagement through code-free social quests. This strategic acquisition brings Ludo’s innovative technology into the Xsolla portfolio, combining its questing tools with Xsolla’s Web Shop and other Xsolla Rewards Solutions to help developers worldwide increase player engagement, drive retention, and unlock new monetization opportunities beyond the traditional app store model. As the #1 web shop provider in the video games industry, with over 500 web shops launched, Xsolla and Ludo will take mobile players' experience to the next level for game developers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508807800/en/
(Graphic: Xsolla)
Ludo’s integration with Xsolla centers on incorporating Community Quests into Xsolla’s ecosystem, giving developers a simple, built-in way to spark engagement through gamified social experiences. This aligns Ludo’s expertise in player activation with Xsolla’s robust commerce infrastructure, creating a seamless path from gameplay to web-based purchases and turning community participation into revenue-generating behavior.
The timing is significant. New platform flexibility allows mobile developers in the U.S. to promote and link to their web shops directly from their games, unlocking more seamless access to external purchasing experiences. This shift means developers can now:
- Connect players directly from mobile games to web shops
- Offer mobile-first access to alternative payment methods
- Expand reach through localized pricing and regional distribution
- Enable one-tap access to specific SKUs, bundles, or promotions
- Customize web-based offers tied to in-game moments and player behavior
With these capabilities combined with Ludo’s community-driven questing tools, developers can now create full-circle engagement loops that increase monetization, drive loyalty, and grow their player base without adding development overhead.
“Welcoming Ludo to the Xsolla family strengthens our push to give mobile game developers accessible, innovative tools,” said Chris Hewish, Chief Strategy Officer at Xsolla. “With an expanded Xsolla Rewards ecosystem, we’re adding loyalty and questing features that turn player engagement into lasting growth for games and their communities. The integration empowers developers to create dynamic quests that reward players for in-game purchases, social participation, and community-building actions such as joining a Discord channel or engaging on social networks. This opens up new avenues for re-engagement, loyalty, and increased conversion, all without requiring additional development resources or burdens on game developers.”
“Player loyalty is shaped the moment or even before the game begins; a dynamic questing system rekindles that spark every day, turning fleeting engagement into a sustainable, ever-growing community,” said Renee Russo, Co-Founder and Co-CEO of Ludo.
“By adding advanced community quests and rewards at checkout, developers can nurture their communities, raise conversion rates, and protect margins,” said Annie Reardon, Co-Founder and Co-CEO of Ludo. “Xsolla remains at the forefront of game commerce, and we’re thrilled to team up – blending rich out-of-game experiences with steady, player-driven growth to drive user acquisition and incremental revenue opportunities for games around the globe.”
In the coming months, Xsolla will continue rolling out tools and integrations built on Ludo’s capabilities, simplifying implementation and providing developers with actionable, data-driven insights. The goal is to give developers of all sizes the ability to grow their games, increase lifetime player value, and build vibrant, engaged communities.
For more information or to begin integrating Ludo, please visit: xsolla.pro/ludo
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250508807800/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press Release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press Release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press Release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press Release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom